{"corpus_id":43468002,"paper_sha":"62d6a285a0ebe3f04c0232958221cb995548fe19","doi":"10.1016/j.jphs.2015.03.004","arxiv_id":null,"pmid":25850380,"pmcid":null,"mag_id":2010378159,"dblp_id":null,"acl_id":null,"title":"Interaction between anti-Alzheimer and antipsychotic drugs in modulating extrapyramidal motor disorders in mice.","year":2015,"publication_date":"2015-04-01","venue":"Journal of Pharmacological Sciences","journal":{"name":"Journal of pharmacological sciences","pages":"\n          439-45\n        ","volume":"127 4"},"journal_issn":null,"journal_title":null,"publication_types":["JournalArticle"],"pubmed_pub_types":["Journal Article","Research Support, Non-U.S. Gov't"],"s2_fields_of_study":["Medicine"],"reference_count":39,"citation_count":29,"influential_citation_count":0,"is_open_access":false,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Alzheimer Disease","mj":false,"qs":[{"q":"drug therapy","mj":false,"ui":"Q000188"}],"ui":"D000544"},{"d":"Animals","mj":false,"ui":"D000818"},{"d":"Antipsychotic Agents","mj":false,"qs":[{"q":"adverse effects","mj":true,"ui":"Q000009"}],"ui":"D014150"},{"d":"Basal Ganglia Diseases","mj":false,"qs":[{"q":"chemically induced","mj":true,"ui":"Q000139"}],"ui":"D001480"},{"d":"Cholinesterase Inhibitors","mj":false,"qs":[{"q":"adverse effects","mj":true,"ui":"Q000009"}],"ui":"D002800"},{"d":"Donepezil","mj":false,"ui":"D000077265"},{"d":"Dose-Response Relationship, Drug","mj":false,"ui":"D004305"},{"d":"Drug Interactions","mj":false,"ui":"D004347"},{"d":"Galantamine","mj":false,"qs":[{"q":"adverse effects","mj":true,"ui":"Q000009"}],"ui":"D005702"},{"d":"Haloperidol","mj":false,"qs":[{"q":"adverse effects","mj":true,"ui":"Q000009"}],"ui":"D006220"},{"d":"Hypokinesia","mj":false,"qs":[{"q":"chemically induced","mj":false,"ui":"Q000139"}],"ui":"D018476"},{"d":"Indans","mj":false,"qs":[{"q":"adverse effects","mj":true,"ui":"Q000009"}],"ui":"D007189"},{"d":"Male","mj":false,"ui":"D008297"},{"d":"Mice, Inbred Strains","mj":false,"ui":"D008815"},{"d":"Nootropic Agents","mj":false,"qs":[{"q":"adverse effects","mj":true,"ui":"Q000009"}],"ui":"D018697"},{"d":"Piperidines","mj":false,"qs":[{"q":"adverse effects","mj":true,"ui":"Q000009"}],"ui":"D010880"},{"d":"Receptor, Serotonin, 5-HT1A","mj":false,"ui":"D044282"},{"d":"Receptors, Muscarinic","mj":false,"ui":"D011976"},{"d":"Serotonin Agents","mj":false,"qs":[{"q":"adverse effects","mj":false,"ui":"Q000009"}],"ui":"D018490"}],"chemicals":[{"n":"Antipsychotic Agents","ui":"D014150","reg":"0"},{"n":"Cholinesterase Inhibitors","ui":"D002800","reg":"0"},{"n":"Indans","ui":"D007189","reg":"0"},{"n":"Nootropic Agents","ui":"D018697","reg":"0"},{"n":"Piperidines","ui":"D010880","reg":"0"},{"n":"Receptors, Muscarinic","ui":"D011976","reg":"0"},{"n":"Serotonin Agents","ui":"D018490","reg":"0"},{"n":"Galantamine","ui":"D005702","reg":"0D3Q044KCA"},{"n":"Receptor, Serotonin, 5-HT1A","ui":"D044282","reg":"112692-38-3"},{"n":"Donepezil","ui":"D000077265","reg":"8SSC91326P"},{"n":"Haloperidol","ui":"D006220","reg":"J6292F8L3D"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":null,"s2_open_access_landing_url":null,"s2_open_access_license":null,"s2_open_access_status":null,"pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"Antipsychotics are often used in conjunction with anti-Alzheimer drugs to treat the behavioral and psychological symptoms of dementia (BPSD). Here, we examined the effects of cholinesterase inhibitors (ChEIs), donepezil and galantamine, on antipsychotic-induced extrapyramidal side effects (EPS) in mice. The effects of serotonergic agents on the EPS drug interaction were also evaluated. Donepezil (0.3-3 mg/kg) did not induce EPS signs by itself; however, it significantly potentiated bradykinesia induction with a low dose of haloperidol (0.5 mg/kg) in dose-dependent and synergistic manners. Galantamine (0.3-3 mg/kg) elicited mild bradykinesia at a high dose and dose-dependently augmented haloperidol-induced bradykinesia. The EPS potentiation by galantamine was blocked by trihexyphenidyl (a muscarinic antagonist), but not by mecamylamine (a nicotinic antagonist). In addition, the bradykinesia potentiation by galantamine was significantly reduced by (±)-8-hydroxy-2-(di-n-propylamino)-tetralin (a 5-HT1A agonist), ritanserin (a 5-HT2 antagonist), and SB-258585 (a 5-HT6 antagonist). The present results give us a caution for the antipsychotics and ChEIs interaction in inducing EPS in the treatment of BPSD. In addition, second generation antipsychotics, which can stimulate 5-HT1A receptors or antagonize 5-HT2 and 5-HT6 receptors, seem to be favorable as an adjunctive therapy for BPSD.","claims":[{"public_id":"cl_929ab86974bbd866e3238f946c9a315d","status":"active","text":"Donepezil did not induce extrapyramidal side effect signs by itself but dose-dependently and synergistically potentiated bradykinesia induced by a low dose of haloperidol in mice.","confidence":0.94,"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/claims/cl_929ab86974bbd866e3238f946c9a315d"},{"public_id":"cl_21e6bb490d7d7ec9d76dc8cb46d259dd","status":"active","text":"Galantamine elicited mild bradykinesia at a high dose and dose-dependently augmented haloperidol-induced bradykinesia in mice.","confidence":0.92,"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/claims/cl_21e6bb490d7d7ec9d76dc8cb46d259dd"},{"public_id":"cl_5c446404f828063f223ffa7b14d05b2e","status":"active","text":"Second generation antipsychotics that stimulate 5-HT1A receptors or antagonize 5-HT2 and 5-HT6 receptors appear favorable as adjunctive therapy for behavioral and psychological symptoms of dementia.","confidence":0.82,"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/claims/cl_5c446404f828063f223ffa7b14d05b2e"},{"public_id":"cl_a8fdd5771e1ffd4f23cdf82e77373464","status":"active","text":"The galantamine-related potentiation of bradykinesia was significantly reduced by a 5-HT1A agonist, a 5-HT2 antagonist, and a 5-HT6 antagonist.","confidence":0.89,"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/claims/cl_a8fdd5771e1ffd4f23cdf82e77373464"},{"public_id":"cl_1efebfb52a409759f2ec4767f8c2eb8a","status":"active","text":"Trihexyphenidyl blocked galantamine potentiation of haloperidol-induced bradykinesia, whereas mecamylamine did not block it.","confidence":0.9,"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/claims/cl_1efebfb52a409759f2ec4767f8c2eb8a"}],"concepts":[{"public_id":"co_024e886cbd25b460acc1aae969069080","status":"active","name":"5-HT1A agonist","description":"A serotonergic agent represented by (±)-8-hydroxy-2-(di-n-propylamino)-tetralin in the bradykinesia interaction experiments.","types":["serotonergic agent","receptor agonist"],"aliases":["(±)-8-hydroxy-2-(di-n-propylamino)-tetralin"],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_024e886cbd25b460acc1aae969069080"},{"public_id":"co_153e37f7dba0513a6bf722b790e9fa73","status":"active","name":"second generation antipsychotics","description":"Antipsychotic drugs discussed as adjunctive therapy options because of serotonergic receptor actions.","types":["drug class","therapy"],"aliases":[],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_153e37f7dba0513a6bf722b790e9fa73"},{"public_id":"co_33ec2e19aff8bed78d4c592e1d0f9f9a","status":"active","name":"extrapyramidal side effects","description":"Motor side effects evaluated in mice after antipsychotic and anti-Alzheimer drug treatment.","types":["adverse effect"],"aliases":["EPS"],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_33ec2e19aff8bed78d4c592e1d0f9f9a"},{"public_id":"co_3575fa1251ba16d58204128096e1d76b","status":"active","name":"behavioral and psychological symptoms of dementia","description":"Dementia-related symptoms for which antipsychotics are used with anti-Alzheimer drugs in the paper context.","types":["clinical condition","symptom group"],"aliases":["BPSD"],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_3575fa1251ba16d58204128096e1d76b"},{"public_id":"co_3b9abaa316c4f9659e0949f8642a13bd","status":"active","name":"trihexyphenidyl","description":"A muscarinic antagonist used to test the receptor mechanism of galantamine-related motor effects.","types":["drug","receptor antagonist"],"aliases":[],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_3b9abaa316c4f9659e0949f8642a13bd"},{"public_id":"co_4b4eb10662494a4238bac28e399c87e7","status":"active","name":"galantamine","description":"A cholinesterase inhibitor tested for bradykinesia and interaction with haloperidol in mice.","types":["drug"],"aliases":[],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_4b4eb10662494a4238bac28e399c87e7"},{"public_id":"co_5d194376676882300fbbdafcf9581b09","status":"active","name":"cholinesterase inhibitors","description":"Anti-Alzheimer drugs examined here for effects on antipsychotic-induced motor side effects.","types":["drug class"],"aliases":["ChEIs"],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_5d194376676882300fbbdafcf9581b09"},{"public_id":"co_68eb746c29e5d40147c7fcd94283da8d","status":"active","name":"donepezil","description":"A cholinesterase inhibitor tested for effects on extrapyramidal signs and haloperidol-induced bradykinesia.","types":["drug"],"aliases":[],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_68eb746c29e5d40147c7fcd94283da8d"},{"public_id":"co_a4e91358c80fceeb1dadcc960c2928f2","status":"active","name":"bradykinesia","description":"Slowness of movement measured as an extrapyramidal motor sign in the mouse experiments.","types":["motor symptom","outcome"],"aliases":[],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_a4e91358c80fceeb1dadcc960c2928f2"},{"public_id":"co_be8b5bfdc26d9903dd0a9f0abb03ffdb","status":"active","name":"mecamylamine","description":"A nicotinic antagonist used to test whether nicotinic mechanisms mediated the galantamine interaction.","types":["drug","receptor antagonist"],"aliases":[],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_be8b5bfdc26d9903dd0a9f0abb03ffdb"},{"public_id":"co_c2ee690bcb98133bc35cae841ce02faa","status":"active","name":"haloperidol-induced bradykinesia","description":"Reduced movement caused by haloperidol treatment and used as an extrapyramidal motor outcome in mice.","types":["outcome","motor disorder"],"aliases":[],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_c2ee690bcb98133bc35cae841ce02faa"},{"public_id":"co_c9db4767617e4430ef654f3c67c80d86","status":"active","name":"5-HT2 antagonist","description":"A serotonergic antagonist represented by ritanserin in the bradykinesia interaction experiments.","types":["serotonergic agent","receptor antagonist"],"aliases":["ritanserin"],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_c9db4767617e4430ef654f3c67c80d86"},{"public_id":"co_d9e63557d55ea4c26bfbc696f9431984","status":"active","name":"5-HT6 antagonist","description":"A serotonergic antagonist represented by SB-258585 in the bradykinesia interaction experiments.","types":["serotonergic agent","receptor antagonist"],"aliases":["SB-258585"],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_d9e63557d55ea4c26bfbc696f9431984"}],"external_ids":{"DOI":"10.1016/j.jphs.2015.03.004","ArXiv":null,"PubMed":25850380,"PubMedCentral":null,"MAG":2010378159,"DBLP":null,"ACL":null},"open_access":{"is_open_access":false,"pdf_url":null,"landing_url":"https://sah.borca.ai/papers/43468002","source":null,"pdf_url_source":null,"license":null,"reason":"pdf_url_not_indexed"},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":631683,"paper_uid":"ab4ad6c6-40d6-47ec-8871-bb5e7d1d6e31","canonical_identity":{"paper_id":631683,"paper_uid":"ab4ad6c6-40d6-47ec-8871-bb5e7d1d6e31","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/43468002"}